Skip to main navigation Skip to search Skip to main content

2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice

  • Ilaria Pennacchia
  • , Arnaldo Carbone
  • , Arcangelo Di Cerbo
  • , Fabio Maria Vecchio
  • , Vincenzo Arena*
  • *Corresponding author

Research output: Contribution to journalArticle

Abstract

The release of the new ASCO/CAP guideline recommendations for human epidermal growth factor receptor 2 testing has led to clearer descriptive definitions for immunohistochemistry categories. As soon as we started to use them we realized that an increase in the number of ISH test was occurring. Herein we report our lab data obtained by comparing the semester after the release of the new guidelines with the same semester of the previous year. The impact on routine work practice is highlighted.
Original languageEnglish
Pages (from-to)285-286
Number of pages2
JournalTHE BREAST
Volume24
Issue number3
DOIs
Publication statusPublished - 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

  • Surgery

Keywords

  • ASCO/CAP
  • Breast Neoplasms
  • Early Detection of Cancer
  • ErbB-2
  • Female
  • Guidelines
  • HER2
  • Humans
  • Neoplasm Proteins
  • Physicians'
  • Practice Guidelines as Topic
  • Practice Patterns
  • Receptor

Fingerprint

Dive into the research topics of '2013 ASCO/CAP updated guidelines for human epidermal growth factor receptor 2 testing: Impact on routine practice'. Together they form a unique fingerprint.

Cite this